CD19- CD45low/- CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells

Leukemia

Volumn 26, Issue 12, 2012, Pages 2530-2537

  Kim, D ^a   Park, C Y ^a,b   Medeiros, B C ^a   Weissman, I L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

multiple myeloma; myeloma initiating cells; xenotransplantation

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE GRAFT; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL LINEAGE; CELL POPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD19; ANTIGENS, CD38; ANTIGENS, CD45; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; FEMALE; FETUS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; PLASMA CELLS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNDECAN-1; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84871238560     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.140     Document Type: Article

References (48)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
2. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 2011; 108: 6468-6473.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
4. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
5. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
6. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-1020.
7. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
8. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 14016-14021.
9. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
10. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97: 7521-7526.
11. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
12. Rajkumar SV. Treatment of relapsed or refractory multiple myeloma. In: Kyle RA, Basow DS (eds) UpToDate. UpToDate: Waltham, MA, 2011.
13. Feo-Zuppardi FJ, Taylor CW, Iwato K, Lopez MH, Grogan TM, Odeleye A et al. Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 1992; 80: 2843-2850.
14. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
15. Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, Taylor BJ et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002; 30: 221-228.
16. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998; 92: 2908-2913.
17. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 1998; 103: 335-342.
18. Park CY, Majeti R, Weissman IL. In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood. Nat Protoc 2008; 3: 1932-1940.
19. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-3182.
20. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978.
21. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-197.
22. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94: 3576-3582.
23. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004; 18: 1891-1897.
24. Huang SY, Tien HF, Su FH, Hsu SM. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system. Am J Pathol 2004; 164: 747-756.
25. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
26. Namikawa R, Ueda R, Kyoizumi S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 1993; 82: 2526-2536.
27. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med 2005; 113: 183-190.
28. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000; 95: 1056-1065.
29. Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44: 2259-2265.
30. Ichim CV, Wells RA. First among equals: the cancer cell hierarchy. Leuk Lymphoma 2006; 47: 2017-2027.
31. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-137.
32. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs Jr KD et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138: 286-299.
33. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S et al. Human lym-phoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-6489.
34. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304: 104-107.
35. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001; 97: 346-351.
36. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986-991.
37. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996; 183: 1399-1406.
38. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171: 1684-1690.
39. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008; 112: 2935-2945.
40. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079-1088.
41. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178: 1023-1031.
42. Chen BJ, Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 1996; 87: 1972-1976.
43. Rasmussen T. The presence of circulating clonal CD19\+ cells in multiple myeloma. Leuk Lymphoma 2001; 42: 1359-1366.
44. Luckey CJ, Bhattacharya D, Goldrath AW, Weissman IL, Benoist C, Mathis D. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci USA 2006; 103: 3304-3309.
45. Reid S, Yang S, Brown R, Kabani K, Aklilu E, Ho PJ et al. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol 2010; 32(6 Pt 1): e190-e196.
46. Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006; 203: 1859-1865.
47. Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 2012; e-pub ahead of print 20 March 2012; doi:10.1038/leu.2012.80.
48. Weissman I. Stem cell research: paths to cancer therapies and regenerative medicine. JAMA 2005; 294: 1359-1366.